GWS
SYRE icon

Glassman Wealth Services’s Spyre Therapeutics SYRE Stock Holding History

Glassman Wealth Services’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed – – 1980
2022
Q1 		$0 Buy
+4
New +$336 ﹤0.01% 1937

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glassman Wealth Services's SYRE Position: Q2 2022 in Review

Glassman Wealth Services sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 4 shares.

Glassman Wealth Services first reported a position in SYRE in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

  • Glassman Wealth Services reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 4 Spyre Therapeutics shares in Q2 2022.
  • Glassman Wealth Services first reported a position in Spyre Therapeutics in Q1 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Spyre Therapeutics position peaked at $0 in Q1 2022.
  • 66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.